$330M Oversubscribed: Ollin’s Faricimab Challenger Just Became the Most Funded Retinal Disease Bet of 2026
Ollin Biosciences closed an oversubscribed $330M Series B on June 24 to run global Phase 3 trials of OLN324...
AbbVie’s Skyrizi Machine Is Writing Checks Its Oncology Pipeline Now Has to Cash
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...
Sanofi’s Tzield Just Opened a Market That Didn’t Exist Last Week
Tzield's FDA approval for stage 3 type 1 diabetes creates a new disease-modifying therapy category for 2.1M U.S. patients...
Disc Medicine’s FDA Meeting Just Reset the Bitopertin Timeline: What the Street Should Actually Be Watching
After a Feb 2026 CRL rejection, Disc Medicine secured FDA alignment on a Phase 3 pathway for bitopertin in...
mRNA 2.0 Is Not a Science Story — It’s a $31 Billion Platform Bet That Most Pipelines Aren’t Priced For
Nature Reviews Drug Discovery maps mRNA's expansion into enzyme replacement and cancer immunotherapy—here's what it means for pipeline valuations...
The Regulatory Data Gap Is Now a Competitive Moat — and Most Sponsors Are on the Wrong Side of It
Nature Reviews Drug Discovery's 2026 RWE framework signals a regulatory inflection point: sponsors who master data infrastructure will compress...
The Triple Threat: Incretin Multi-Agonists Are About to Redraw the $77B Obesity Map
Nature Reviews flags incretin multi-agonist reversal of obesity and diabetes — Lilly's retatrutide Phase 3 data signals the GLP-1...
Jupiter Neurosciences’ $100M ALA-002 Bet Is a Regulatory Arbitrage Play, Not a Science Story
Jupiter Neurosciences (JUNS) just licensed ALA-002, a Novel Chemical Entity MDMA, for $100M+—here's why the NCE status matters more...
Regeneron’s Fianlimab Flop Rewrites the LAG-3 Playbook — and Bristol-Myers Just Got Luckier
Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...
Innovent’s Triple Breakthrough Play: IBI363 Just Became the Most Dangerous Asset in Immuno-Oncology’s Coldest Corner
Innovent's IBI363 scores its third NMPA Breakthrough Therapy Designation—this time for MSS/pMMR colorectal cancer, the tumor type that killed...